Background. Prophylactic and preemptive strategies are used to prevent cytomegalovirus (CMV) infections after solid organ transplant. We assessed the safety and efficacy of both strategies for CMV prevention.
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Background. Prophylactic and preemptive strategies are used to prevent cytomegalovirus (CMV) infections after solid organ transplant. We assessed the safety and efficacy of both strategies for CMV prevention.
Methods. A DerSimonian and Laird random-effects model was used for pooling the data, and Q statistic and I 2 methods were used to assess statistical heterogeneity.
Results. Twenty studies (2744 patients) were selected for the direct analysis and 20 studies (2544 patients) for the indirect analysis. The odds of CMV syndrome (odds ratio [OR] = 1.10; 95% confidence interval [CI] , .60-2.03; P = .757; Q = 18.55; I 2 = 51.5%) and disease (OR = 0.77; 95% CI, .41-1.47; P = .432; Q = 32.71; I 2 = 45.0%) were not significantly different between strategies. The odds of developing late-onset CMV infections were higher for the prophylactic compared to the preemptive strategy (OR = 6.21; 95% CI, 2.55-15.20; P < .0001; Q = 9.66; I 2 = 37.9%). The odds of CMV viremia were lower for prophylaxis (OR = 0.42; 95% CI, .24-.74; P = .003; Q = 48.10; I 2 = 75.1%) than preemptive therapy. No differences between strategies were noted for graft loss (OR = 0.88; 95% CI, .37-2.13; P = .779; Q = 13.03, I 2 = 38.6%), graft loss censored for death (OR = 0.73; 95% CI, .17-3.21; P = .679; Q = 4.48; I 2 = 55.3%), acute rejection (OR = 0.93; 95% CI, .70-1.24; P = .637; Q = 12.99; I 2 = 7.6%), or mortality (OR = 0.80; 95% CI, .56-1.14; P = .220; Q = 8.76; I 2 = 0%). The odds for other infections (herpes simplex virus, varicella zoster virus, bacterial and fungal infections) did not significantly differ between strategies. Leukopenia (OR = 1.97; 95% CI, 1.39-2.79; P = .0001; Q = 7.10; I 2 = 0%) and neutropenia (OR = 2.07; 95% CI, 1.13-3.78; P = .018; Q = 6.77; I 2 = 11.4%) were more frequent with prophylaxis than with the preemptive strategy. The results of direct and indirect comparisons were consistent.
Conclusions. Prophylaxis was associated with less early posttransplant viremia, but significantly more late-onset CMV infections and side effects (leukopenia and neutropenia) than the preemptive strategy. Both preventive strategies showed similar efficacy in preventing CMV syndrome and disease, with no differences regarding rejection, graft loss, death, or opportunistic infections.
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Cytomegalovirus (CMV) infection remains the most vexing opportunistic infection following solid organ transplant [1] . Despite major progress made regarding immunosuppressive regimens and diagnostic assays, depending on CMV serostatus and allograft type, up to one-third of patients develop CMV disease during the first year after transplant [2] [3] [4] . Two preventive strategies have been used to prevent CMV infections after transplant. Universal prophylaxis involves the administration of an antiviral drug 1-4 times daily for 3 to 6 months for patients at high risk for developing this infection, whereas the preemptive approach comprises of monitoring viremia in a systematic way and administering antivirals only if patients develop CMV replication. Advocates of each of these 2 strategies have published a multitude of studies, editorials, and narrative reviews, but the previous lack of comparative data and its consequent uncertainty have further fueled this controversy.
Since the publication of our first meta-analysis in this journal in 2005 [1] , a large number of comparative studies on this subject have been published. To reduce this scientific uncertainty and bring light to this critical problem that affects thousands of patients every year, we performed a new systematic review and meta-analysis with the primary aim to compare universal prophylaxis to the preemptive strategy. Our new study not only offers a much larger sample size than before, but also provides a more inclusive statistical methodology, which allowed us to analyze all available literature through both direct and indirect treatment comparison meta-analyses.
METHODS

Literature Search
PubMed (Medline, PreMedline, and Old Medline), Embase (covers 1974 to the present), and all the Cochrane Library databases were searched from earliest included records through 30 November 2012 (by authors C.M.S. and D.F.F.). Search strategies utilized a combination of keywords, subject headings, and other indexing terms to represent the "cytomegalovirus," "solid organ transplant," "prophylaxis or preemptive therapy," and "control or comparison group" concepts. Full search strategies are shown in Supplementary Appendix 1. A total of 8001 records were retrieved by the searches: 1266 from PubMed, 6204 from Embase, and 531 from the Cochrane Library. Of these, 1633 were duplicates. After removal of the duplicates, the remaining 6368 records were subjected to a quick title/abstract review by C.M.S. and D.F.F. A total of 1072 potentially relevant records were identified. An article was considered potentially relevant if it was a clinical guideline, consensus report, systematic review, meta-analysis, or primary report of data and compared the results of 2 different methods for handling CMV prevention or preemption in solid organ transplant recipients. The PRISMA criteria were used for the search and flow of studies. (Figure 1 ).
Study Selection
Inclusion criteria were randomized controlled trials that evaluated preventive strategies of CMV in solid organ transplant. Exclusion criteria were (1) <2 g/day of acyclovir, (2) <3 g/day of ganciclovir for universal prophylaxis, (3) universal prophylaxis for <60 days, (4) preemptive therapy for <14 days, (5) assessed efficacy of immunoglobulin alone or in combination with antiviral drugs as the primary endpoint, and (6) use of universal prophylaxis or preemptive therapy in both arms.
Definitions
The definitions for CMV infection, viremia, syndrome, and disease were based on the American Society of Transplantation recommendations [5] . CMV viremia was the trigger for the preemptive strategy. The definitions of bacterial, fungal, and other viral infections were based on the definitions in the original studies. Rejection was considered to be biopsy-proven acute allograft rejection reported up to 12 months.
Outcomes
The primary outcome was the efficacy of prophylaxis vs preemptive therapy in preventing CMV syndrome and invasive CMV disease. Secondary outcomes were: efficacy of prophylaxis vs preemptive therapy in preventing CMV viremia, the impact on the time to onset of CMV infections and the rate of other infections, and comparison of the rate of side effects (leukopenia and thrombocytopenia).
Statistical Analysis
The meta-analysis was conducted using the metafor package for R developed by Wolfgang Viechtbauer [6] . The direct comparison meta-analysis was defined by the inclusion of studies that compared the 2 preventive strategies directly against each other. The indirect comparison meta-analysis was defined by the inclusion of studies that compared one preventive strategy against controls or placebo. Both direct and indirect comparisons preserved the assignment and/or randomization of the original patient groups. The data were pooled using a DerSimonian and Laird random-effects model for all studies, which accounts for variability both within and between studies [7] . The Q statistic method and I 2 method were used to assess statistical heterogeneity. For studies with no event of interest in a treatment group, 0.5 was added to all cells. For studies providing median and range only for continuous outcomes, mean value and variance were estimated using the median and range [8] . Binary outcome results were expressed as odds ratios (ORs) between 2 groups, and continuous outcomes results were expressed as standardized mean difference between 2 groups. Egger regression and Begg and Mazumdar methods were used to evaluate publication bias. Forest plots were created for outcome data. We also performed an adjusted indirect comparison for the 2 common comparators ( placebo or no drug) using the Bucher technique [9] . We planned a priori subset analysis based on the type of allograft, CMV diagnostic test, study design, if the prophylaxis was followed by preemptive strategy, type of drug used for prophylaxis, length of prophylaxis, and length of preemptive therapy.
RESULTS
A total of 40 studies were included: 20 studies (2744 patients) [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] were selected for the direct analysis, and 20 studies (2544 patients) [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] for the indirect analysis (Table 1, Supplementary Table) .
Universal Prophylaxis vs Preemptive Strategy: Direct Comparison
Primary Outcomes
The odds for CMV syndrome (10 studies, 1803 patients) and invasive CMV disease (19 studies, 2110 patients) did not significantly differ between the prophylactic and preemptive groups (OR = 1.10; 95% confidence interval [CI], .60-2.03; P = .757; Q = 18.55; I 2 = 51.5%; P = .03 and OR = 0.77; 95% CI, .41-1.47; P = .432; Q = 32.71; I 2 = 45.0%; P = .02, respectively;
Figures 2 and 3). The odds for late-onset CMV disease (7 studies, 999 patients) were higher for the prophylactic group compared to the preemptive group (OR = 6.21; 95% CI, 2.55-15.20; P < .0001; Q = 9.66; I 2 = 37.9%; P = .14; Figure 4 ). 
Secondary Outcomes
The odds for CMV viremia (13 studies, 1711 patients) were lower for prophylaxis compared to the preemptive strategy (OR = 0.42; 95% CI, .24-.74; P = .003; Q = 48.10; I 2 = 75.1%; P = .0001; Figure 5 ). No differences between the prophylactic and preemptive groups were noted regarding the following: graft loss (9 studies, 1005 patients; OR = 0.88; 95% CI, .37-2.13; P = .779; Q = 13.03, I 2 = 38.6%; P = .11), graft loss censored for death (3 studies, 623 patients; OR = 0.73; 95% CI, .17-3.21; P = .679; Q = 4.48; I 2 = 55.3%; P = .11), acute rejection (13 studies, 1638 patients; OR = 0.93; 95% CI, .70-1.24; P = .637; Q = 12.99; I 2 = 7.6%; P = .37), or mortality (13 studies, 2193 patients; OR = 0.80; 95% CI, .56-1.14; P = .220; Q = 8.76; I 2 = 0%; P = .72). The prophylactic group had more leukopenia (9 studies, 1022 patients; OR = 1.97; 95% CI, 1.39-2.79; P = .0001; Q = 7.10; I 2 = 0%; P = .53) and neutropenia (7 studies, 1054 patients; OR = 2.07; 95% CI, 1.13-3.78; P = .018; Q = 6.77; I 2 = 11.4%; P = .34; Figure 2E ) compared to the preemptive group ( Figures 6 and 7) .
Subgroup Analysis
The results of the subgroup analysis for cytomegalovirus viremia in patients who received universal prophylaxis vs preemptive therapy are presented in Table 2 . These results should be interpreted cautiously due to their exploratory nature and potential for multiplicity. No advantage for either strategy was found for the prevention of CMV syndrome or CMV disease (Table 3) .
Time to Onset of CMV Infections
The prophylactic group had a longer standardized mean time (in days) to CMV viremia (6 studies, 223 patients; SMD = 2.93; 95% CI, 1.22-4.63; P = .0008; Q = 90.90, I 2 = 94.5%; P < .0001), CMV syndrome (2 studies, 30 patients; SMD = 2.09; 95% CI, 1.16-3.02; P < .0001; Q = 0.70, I 2 = 0%; P = .40), and CMV disease (2 studies, 24 patients; SMD = 2.24; 95% CI, 1.10-3.38; P = .0001; Q = 0.66, I 2 = 0%; P = .42) compared to the preemptive group.
Other Infections
The odds for other infections were not significantly different between the prophylactic and preemptive strategies: herpes simplex virus 
Universal Prophylaxis vs Preemptive Strategy: Indirect Comparison
One of the assumptions of adjusted indirect comparison metaanalyses is that the included trials of prophylactic and preemptive strategies were relatively comparable. We compared the characteristics of the controls in the included trials to determine if these results could be influential on the efficacy and safety events in this population (Table 4) .
Primary Outcomes
The odds for CMV syndrome (9 vs 7 studies, 1294 vs 406 patients; OR = 1.46; 95% CI, .66-3.21; P = .351; Q = 0.87; P = .35), CMV disease (14 vs 8 studies, 2259 vs 475 patients; OR = 0.75; 95% CI, .32-1.75; P = .501; Q = 0.45; P = .50), and late-onset CMV infections (7 vs 1 studies, 1775 vs 80 patients; OR = 1.23; 95% CI, .30-4.97; P = .77) were not significantly different between the universal prophylactic and preemptive groups.
Secondary Outcomes
The odds for CMV viremia (6 vs 4 studies, 885 vs 294 patients; OR = 0.86; 95% CI, .19-1.12; P = .088; Q = 3.47; P = .50) favored prophylaxis but the difference was not statistically significant.
No differences between the prophylactic and preemptive groups were noted regarding allograft loss censoring for death ( 
Subgroup Analysis
No differences between the prophylactic and preemptive groups were noted for CMV viremia, CMV syndrome, or CMV disease in the following subset analyses by the allograft type, CMV diagnostic test, study design, type of drug used in the prophylactic arm, and length of prophylaxis (Table 5 ).
Time to CMV Infections
The standardized mean times (days) to onset of CMV viremia (2 studies vs 1 study, 60 vs 28 patients; SMD = 2.65; 95% CI, −3.84 to 9.14; P = .42) and CMV disease (3 studies vs 1 study, 200 vs 7 
Other Infections
The odds for other infections did not significantly differ between the prophylactic and preemptive strategies: HSV infections (9 studies vs 1 study, 1934 vs 65 patients; OR = 0.10; 95% CI, .004-2.62; P = .167) , bacterial infections (3 vs 2 studies, 367 vs 100 patients; OR = 0.37; 95% CI, .04-3.29; P = .372; Q = 4.07; P = .04) , fungal infections (3 studies vs 1 study, 367 vs 40 patients; OR = 1.84; 95% CI, .07-50.19; P = .718).
DISCUSSION
The main finding of both the direct and indirect comparison analyses demonstrate that prophylactic and preemptive strategies are equally effective in preventing CMV syndrome and end-organ disease with the current available antiviral drugs; these results remained consistent within each allograft, including kidney, liver, heart, and lung transplant. Second, prophylaxis, particularly short-term prophylaxis, is more effective than preemptive strategy in preventing CMV viremia; however, this did not translate into fewer CMV syndrome or end-organ disease events. In the subset analysis by the allograft type, a significant reduction of CMV viremia with prophylaxis remained present only in kidney transplant recipients, which represented the majority of the population. All drugs (acyclovir, valacyclovir, ganciclovir [GCV], and valganciclovir [VGC]) used for prophylaxis had similar efficacy in reducing CMV viremia and CMV disease. We could not compare the efficacy of prophylaxis with VGC at different doses (450 mg vs 900 mg) vs preemptive therapy, as only 1 study administered 450 mg daily VGC. However, we reported in a previous meta-analysis that VGC 900 mg daily has similar efficacy compared to VGC 450 mg daily, and was not superior to GCV prophylaxis or preemptive treatment; in addition, the higher dose of VGC was associated with increased risk of leukopenia and allograft rejection [50] .
In contrast with the meta-analysis performed by Zhang et al [51] , we focused on clinically significant events, CMV syndrome, and end-organ disease rather than the total number of nonspecific infections: that is, Zhang et al lumped together viremia, syndrome, and disease; this total number of CMV infections was mainly driven and overrepresented by CMV viremia, which would mislead one to the conclusion that prophylaxis would be more effective than preemptive strategy. In addition, unlike Zhang et al, we did not limit our studies to only renal transplant recipients. Moreover, we looked at the impact of these strategies on late-onset CMV infections and we noted a significantly higher rate of these late infections with prophylaxis compared with preemptive strategy. Late CMV infections remain a major problem in transplantation, especially in patients receiving universal prophylaxis, which delays the CMV reactivation or primary infection. In the last few years, programs have started using sequential prophylactic-preemptive treatment regimens, in an attempt to prevent the late-onset CMV infections [16] , although there is limited evidence to support this approach. Our subgroup analysis suggested that patients with prophylaxis followed by preemptive therapy were less likely to have viremia than the patients with preemptive therapy alone; however, both 95% CIs overlapped. Additional studies need to be performed to evaluate these findings.
When subset analysis was performed by CMV serostatus, prophylaxis was favored over the preemptive approach for donor-positive/recipient-negative (D+/R−) and recipientpositive (R+) recipients in the direct comparison. Antiviral prophylaxis is recommended as the preferred preventive strategy in D+/R− recipients according to the last American Society of Transplantation guidelines [4, 52] . Preemptive therapy in high-risk patients is still controversial, as these patients need close monitoring of CMV viral load or antigenemia, and appropriate and rapid treatment, but it is considered an option by the same guidelines [4, 52] . From our data, it can be seen that with prophylaxis the D+/R− recipients at are lower risk for CMV viremia and CMV disease, but they are at higher risk for development of late-onset CMV disease. Late-onset CMV disease in D+/R− or R+ recipients is a safety concern as it has been associated with increased mortality during the first year following transplant [53, 54] . These results suggest that perhaps a hybrid strategy should be further studied in D+/R− and R+ recipients to assess its impact on mortality and allograft outcomes. When the analysis was subgrouped by diagnostic method, the polymerase chain reaction (PCR) analysis favored prophylaxis over the preemptive strategy. Most of the studies included in the indirect analysis used pp65 antigen and/or CMV culture as diagnostic methods, whereas in the direct comparison, most included PCR and/or pp65 antigen. Although pp65 antigen is still used in some centers, most hospital laboratories have switched diagnostic testing to quantitative PCR [55] . Pang et al showed that there was significant interlaboratory variability regarding CMV quantitative PCR-based measurements [55] ; this makes comparison of the results among different institutions difficult, and indirectly has an impact on the prevention and management of CMV infections. In November 2010, an international standard for CMV PCR-based diagnostic tests was developed and approved by the World Health Organization, which will lead to improvement in the agreement of viral load values between laboratories [56] .
Another important finding of our meta-analysis is that the risk for different infections (HSV, VZV, and other viruses; bacteria; and fungi) did not significantly differ between the prophylactic and preemptive strategies. Additionally, the type of preventive strategy did not have an impact on graft loss, graft loss censored for death, acute rejection, or mortality rates. Previous studies have shown that late CMV disease in patients on GCV or VGC prophylaxis was associated with poor allograft outcome and increased mortality during the first posttransplant year [53, 54] . In our meta-analysis, the mortality was not different according to the strategy of prevention; this could be due to inclusion of patients with different CMV serostatus, or due to the low rate of events. These results are not surprising if we consider that prophylaxis is associated with a higher rate of lateonset CMV infections, whereas preemptive strategy is associated with a higher rate of early CMV viremia episodes. CMV has immunomodulatory effects through an encoded homologue of interleukin 10 (IL-10) with high affinity for the human IL-10 receptor that leads to decreased T-cell mitogen-stimulated proliferative activity, proinflammatory cytokine production, and human leukocyte antigen surface expression [57, 58] . This may result in increased predisposition to opportunistic infections [1, [59] [60] [61] . The indirect immunomodulatory effects of CMV would explain graft rejection through allograft infiltration by lymphocytes and increased expression of major histocompatibility complex class II [62, 63] . With the introduction of CMV prophylaxis, there was a shift toward late-onset CMV infections, 1-2 months after prophylaxis was discontinued. From the available data, it is not clear if such a shift was seen with all the opportunistic infections and allograft rejections as time to these outcomes was not collected and compared between the 2 preventive strategies.
The prophylactic group had statistically significant longer times to CMV viremia (2.93 days), CMV syndrome (2.09 days), and CMV disease (2.24 days) than the preemptive group; however, these differences were not clinically significant based on such a small time difference. CMV viremia is used in clinical practice to trigger preemptive therapy (the base for preemption therapy) and as a marker of CMV syndrome or disease after solid organ transplant, as well as to monitor response to treatment. This result highlights the need for new tests to diagnose CMV infection before viremia becomes detectable; this might have important implications for its pathogenesis, as CMV is an immunomodulatory virus that could trigger allograft rejection and alter immunity, leading to more opportunistic infections.
Prophylaxis was associated with significantly more side effects (leukopenia and neutropenia) compared with the preemptive strategy. The rates of leukopenia and neutropenia were likely underestimated due to the variability of the chosen threshold to collect data, lack of systematic blood collection, and inconsistent reporting across studies. Additionally, the magnitude of leukopenia and neutropenia and its consequent developing of further opportunistic infections could not be directly evaluated. This brings safety concerns that will need to be addressed in future CMV prevention trials.
The results from the indirect comparison meta-analysis fully support the findings of the direct comparison meta-analysis; that is, there was no difference in the rates of CMV viremia, CMV syndrome, CMV disease, other infections, allograft loss censoring for death, acute rejection, mortality, or side effects between the 2 preventive approaches. These results remained consistent in the subsequent subgroup analysis. The only difference was found regarding CMV viremia, which was probably due to fewer studies reporting it within the indirect analysis. We initially assumed that the trials included in the indirect meta-analysis were more comparable. Contrary to our expectations, we found significant differences in the immunosuppressive regimens between the controls that would suggest better efficacy with the preemptive strategy compared to prophylaxis-that is, similar efficacy to prevent CMV was found despite more profound immunosuppression with the preemptive approach.
Limitations
The heterogeneity between the studies was moderate to high, and not changed by the subgroup analyses; this was probably due to inclusion of several types of allografts, patients with diverse underlying diseases, and different studies designs. Multiple testing due to the number of subgroup analyses could have led to false-positive results; hence it should be emphasized that the P values from the subgroup analyses were exploratory and should be viewed with caution. CMV resistance was not evaluated because most of the studies did not report it. The exact level of viremia and its potential dose-effect on outcomes could not be evaluated as most of the studies did not report it. The reliability of these preventive strategies could not be evaluated in intestinal transplant recipients.
What are the clinical implications of our results? How can we improve CMV prevention? Both strategies depend on patients' compliance and the transplant program's infrastructure and costs. Of note, costs have a significant influence on the choice of preventive strategy worldwide. Prophylaxis is associated with more side effects, whereas preemptive strategy requires a more dedicated infrastructure to monitor the patients. First, we could improve the prophylactic approach if new drugs with at least similar efficacy but better safety profile, lower cost, and easier dosing schedule could be developed. Second, we could improve the preemptive approach if the costs of PCR monitoring would be lower and patients' adherence higher. Last, the introduction of CMVspecific immune monitoring strategies might be able to identify CMV reactivation at an earlier stage than can be accomplished with plasma PCR or pp65 antigen.
CONCLUSIONS
Prophylaxis was associated with less early posttransplant viremia, but with significantly more late-onset CMV infections and side effects (leukopenia and neutropenia) than the preemptive strategy. We did not detect a statistically significant difference in the effectiveness of preventing CMV syndrome and end-organ disease between the prophylactic and preemptive strategies, although the benefit was heterogeneous among the studies; for some patients one strategy might be preferred over the other.
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